CO2018013240A2 - Oligonucleótidos antisentido para modular la expresión de htra1 - Google Patents
Oligonucleótidos antisentido para modular la expresión de htra1Info
- Publication number
- CO2018013240A2 CO2018013240A2 CONC2018/0013240A CO2018013240A CO2018013240A2 CO 2018013240 A2 CO2018013240 A2 CO 2018013240A2 CO 2018013240 A CO2018013240 A CO 2018013240A CO 2018013240 A2 CO2018013240 A2 CO 2018013240A2
- Authority
- CO
- Colombia
- Prior art keywords
- antisense oligonucleotides
- modulate
- htra1
- htra1 expression
- expression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a oligonucleótidos (oligómeros) antisentido que son complementarios a HTRA1, que conducen a la modulación de la expresión de HTRA1. La modulación de la expresión de HTRA1 resulta beneficiosa para un abanico de trastornos médicos, tales como la degeneración macular, por ejemplo la degeneración macular asociada a la edad.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16177508 | 2016-07-01 | ||
EP17170129 | 2017-05-09 | ||
PCT/EP2017/065937 WO2018002105A1 (en) | 2016-07-01 | 2017-06-28 | Antisense oligonucleotides for modulating htra1 expression |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2018013240A2 true CO2018013240A2 (es) | 2018-12-14 |
Family
ID=59295175
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2018/0013240A CO2018013240A2 (es) | 2016-07-01 | 2018-12-06 | Oligonucleótidos antisentido para modular la expresión de htra1 |
Country Status (21)
Country | Link |
---|---|
US (2) | US10519450B2 (es) |
EP (1) | EP3478839A1 (es) |
JP (3) | JP7060525B2 (es) |
KR (1) | KR20190025970A (es) |
CN (1) | CN109415732B (es) |
AU (1) | AU2017289204A1 (es) |
BR (1) | BR112018077321A2 (es) |
CA (1) | CA3026855A1 (es) |
CL (1) | CL2018003698A1 (es) |
CO (1) | CO2018013240A2 (es) |
CR (1) | CR20180606A (es) |
IL (1) | IL263489A (es) |
MA (1) | MA45620A (es) |
MX (1) | MX2018015722A (es) |
PE (1) | PE20190381A1 (es) |
PH (1) | PH12018502707A1 (es) |
RU (1) | RU2019101298A (es) |
SG (2) | SG10202005885VA (es) |
TW (1) | TW201803990A (es) |
WO (1) | WO2018002105A1 (es) |
ZA (1) | ZA201808291B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4257191A3 (en) | 2016-06-21 | 2023-11-22 | Orion Ophthalmology LLC | Heterocyclic prolinamide derivatives |
JP7164521B2 (ja) | 2016-06-21 | 2022-11-01 | オリオン・オフサルモロジー・エルエルシー | 炭素環式プロリンアミド誘導体 |
US10519450B2 (en) | 2016-07-01 | 2019-12-31 | Hoffmann-La Roche Inc. | Antisense oligonucleotides for modulating HTRA1 expression |
US11597926B2 (en) | 2017-12-22 | 2023-03-07 | Roche Innovation Center Copenhagen A/S | Thiophosphoramidites |
KR20200104345A (ko) | 2017-12-22 | 2020-09-03 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | 포스포로디티오에이트 뉴클레오시드간 연결을 포함하는 올리고뉴클레오티드 |
AU2018386527A1 (en) | 2017-12-22 | 2020-04-30 | Roche Innovation Center Copenhagen A/S | Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage |
CA3090901A1 (en) | 2018-02-12 | 2019-08-15 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
WO2020007772A1 (en) * | 2018-07-02 | 2020-01-09 | Roche Innovation Center Copenhagen A/S | Antisense oligonucleotides targeting gbp-1 |
WO2020109344A1 (en) * | 2018-11-29 | 2020-06-04 | F. Hoffmann-La Roche Ag | Occular administration device for antisense oligonucleotides |
WO2020109343A1 (en) * | 2018-11-29 | 2020-06-04 | F. Hoffmann-La Roche Ag | Combination therapy for treatment of macular degeneration |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
CA2303299C (en) | 1997-09-12 | 2016-02-23 | Exiqon A/S | Oligonucleotide analogues |
AU5290499A (en) | 1998-08-03 | 2000-02-28 | Novartis Ag | Human htra serine protease |
RU2233844C2 (ru) | 1999-02-12 | 2004-08-10 | Санкио Компани Лимитед | Новые нуклеозидные и олигонуклеотидные аналоги |
DE60033927T2 (de) | 1999-05-04 | 2007-11-29 | Santaris Pharma A/S | L-ribo-lna analoge |
US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
EP2141233B1 (en) | 2002-11-18 | 2016-10-19 | Roche Innovation Center Copenhagen A/S | Antisense design |
WO2006127913A2 (en) | 2005-05-24 | 2006-11-30 | Isis Pharmaceuticals, Inc. | Modulation of lmw-ptpase expression |
WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
PL2314594T3 (pl) | 2006-01-27 | 2014-12-31 | Isis Pharmaceuticals Inc | Zmodyfikowane w pozycji 6 analogi bicykliczne kwasów nukleinowych |
US7666854B2 (en) | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
JP5441688B2 (ja) | 2006-05-11 | 2014-03-12 | アイシス ファーマシューティカルズ, インコーポレーテッド | 5’修飾二環式核酸類似体 |
US20110052602A1 (en) | 2006-07-26 | 2011-03-03 | Yale University | Diagnosis and Treatment of Age Related Macular Degeneration |
WO2008067040A2 (en) | 2006-10-06 | 2008-06-05 | University Of Utah Research Foundation | Method of detecting ocular diseases and pathologic conditions and treatment of same |
EP2913341A1 (en) | 2006-12-22 | 2015-09-02 | University of Utah Research Foundation | Method of detecting ocular diseases and pathologic conditions and treatment of same |
EP2170917B1 (en) | 2007-05-30 | 2012-06-27 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
ES2386492T3 (es) | 2007-06-08 | 2012-08-21 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos carbocíclicos |
TW200911290A (en) * | 2007-07-02 | 2009-03-16 | Alcon Res Ltd | RNAI-mediated inhibition of HTRA1 for treatment of macular degeneration |
US8278283B2 (en) | 2007-07-05 | 2012-10-02 | Isis Pharmaceuticals, Inc. | 6-disubstituted or unsaturated bicyclic nucleic acid analogs |
WO2009059321A2 (en) | 2007-11-01 | 2009-05-07 | University Of Iowa Research Foundation | Rca locus analysis to assess susceptibility to amd and mpgnii |
US8546556B2 (en) | 2007-11-21 | 2013-10-01 | Isis Pharmaceuticals, Inc | Carbocyclic alpha-L-bicyclic nucleic acid analogs |
DK2356129T3 (da) | 2008-09-24 | 2013-05-13 | Isis Pharmaceuticals Inc | Substituerede alpha-L-bicykliske nukleosider |
EP2462153B1 (en) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
EP2580228B1 (en) | 2010-06-08 | 2016-03-23 | Ionis Pharmaceuticals, Inc. | Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
FR2965278B1 (fr) | 2010-09-23 | 2014-10-10 | Univ Caen Basse Normandie | Procede d'obtention in vitro ou ex vivo de chondrocytes et leurs utilisations |
EP2753631A1 (en) | 2011-09-07 | 2014-07-16 | Marina Biotech, Inc. | Synthesis and uses of nucleic acid compounds with conformationally restricted monomers |
US9221864B2 (en) | 2012-04-09 | 2015-12-29 | Isis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
JP2016522674A (ja) | 2012-05-16 | 2016-08-04 | ラナ セラピューティクス インコーポレイテッド | 遺伝子発現を調節するための組成物及び方法 |
CA2889596C (en) | 2012-11-15 | 2022-08-23 | Roche Innovation Center Copenhagen A/S | Oligonucleotide conjugates |
BR112018007703A2 (pt) | 2015-10-30 | 2018-11-06 | Genentech Inc | anticorpos, ácido nucleico isolado, métodos de produção de um anticorpo e de tratamento de um distúrbio, composição farmacêutica, terapia de combinação e uso do anticorpo |
US10519450B2 (en) | 2016-07-01 | 2019-12-31 | Hoffmann-La Roche Inc. | Antisense oligonucleotides for modulating HTRA1 expression |
US20190284621A1 (en) | 2016-11-11 | 2019-09-19 | Roche Innovation Center Copenhagen A/S | Therapeutic oligonucleotides capture and detection |
US20190055564A1 (en) | 2017-06-01 | 2019-02-21 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides for modulating htra1 expression |
-
2017
- 2017-06-28 US US15/635,629 patent/US10519450B2/en active Active
- 2017-06-28 CR CR20180606A patent/CR20180606A/es unknown
- 2017-06-28 KR KR1020197003217A patent/KR20190025970A/ko not_active Application Discontinuation
- 2017-06-28 CN CN201780039864.6A patent/CN109415732B/zh active Active
- 2017-06-28 PE PE2018003308A patent/PE20190381A1/es unknown
- 2017-06-28 WO PCT/EP2017/065937 patent/WO2018002105A1/en unknown
- 2017-06-28 MX MX2018015722A patent/MX2018015722A/es unknown
- 2017-06-28 AU AU2017289204A patent/AU2017289204A1/en not_active Abandoned
- 2017-06-28 SG SG10202005885VA patent/SG10202005885VA/en unknown
- 2017-06-28 JP JP2018568277A patent/JP7060525B2/ja active Active
- 2017-06-28 CA CA3026855A patent/CA3026855A1/en not_active Abandoned
- 2017-06-28 MA MA045620A patent/MA45620A/fr unknown
- 2017-06-28 SG SG11201811554SA patent/SG11201811554SA/en unknown
- 2017-06-28 TW TW106121548A patent/TW201803990A/zh unknown
- 2017-06-28 RU RU2019101298A patent/RU2019101298A/ru not_active Application Discontinuation
- 2017-06-28 BR BR112018077321-2A patent/BR112018077321A2/pt not_active IP Right Cessation
- 2017-06-28 EP EP17736594.7A patent/EP3478839A1/en active Pending
-
2018
- 2018-12-04 IL IL263489A patent/IL263489A/en unknown
- 2018-12-06 CO CONC2018/0013240A patent/CO2018013240A2/es unknown
- 2018-12-07 ZA ZA201808291A patent/ZA201808291B/en unknown
- 2018-12-19 CL CL2018003698A patent/CL2018003698A1/es unknown
- 2018-12-20 PH PH12018502707A patent/PH12018502707A1/en unknown
-
2019
- 2019-12-30 US US16/730,779 patent/US20200399641A1/en not_active Abandoned
-
2022
- 2022-04-14 JP JP2022067085A patent/JP7416852B2/ja active Active
-
2024
- 2024-01-04 JP JP2024000178A patent/JP2024029178A/ja active Granted
Also Published As
Publication number | Publication date |
---|---|
SG10202005885VA (en) | 2020-07-29 |
CR20180606A (es) | 2019-02-14 |
PH12018502707A1 (en) | 2019-11-11 |
JP2022106785A (ja) | 2022-07-20 |
CN109415732A (zh) | 2019-03-01 |
TW201803990A (zh) | 2018-02-01 |
KR20190025970A (ko) | 2019-03-12 |
CL2018003698A1 (es) | 2019-04-05 |
PE20190381A1 (es) | 2019-03-08 |
MA45620A (fr) | 2019-05-08 |
US10519450B2 (en) | 2019-12-31 |
BR112018077321A2 (pt) | 2019-04-24 |
CA3026855A1 (en) | 2018-01-04 |
RU2019101298A (ru) | 2020-08-03 |
WO2018002105A1 (en) | 2018-01-04 |
US20180002701A1 (en) | 2018-01-04 |
EP3478839A1 (en) | 2019-05-08 |
AU2017289204A1 (en) | 2019-01-17 |
US20200399641A1 (en) | 2020-12-24 |
JP2019522987A (ja) | 2019-08-22 |
MX2018015722A (es) | 2019-05-27 |
JP7416852B2 (ja) | 2024-01-17 |
SG11201811554SA (en) | 2019-01-30 |
IL263489A (en) | 2019-01-31 |
JP7060525B2 (ja) | 2022-04-26 |
CN109415732B (zh) | 2024-01-02 |
ZA201808291B (en) | 2019-10-30 |
JP2024029178A (ja) | 2024-03-05 |
RU2019101298A3 (es) | 2021-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018013240A2 (es) | Oligonucleótidos antisentido para modular la expresión de htra1 | |
BR112017012272A2 (pt) | derivados de 2-anilinopirimidina como moduladores de egfr | |
PH12020500252A1 (en) | Compounds as modulators of ror gamma | |
BR112017017396A2 (pt) | derivados substituídos de nucleosídeos substituídos úteis como agentes anticancerígenos | |
DOP2014000277A (es) | Compuestos y composiciones que modulan la actividad del receptor de factor de crecimiento epidérmico (egfr) | |
BR112016014020A8 (pt) | moduladores de tetra-hidropiridopirazinas de gpr6. | |
CO2017005959A2 (es) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
CL2020002719A1 (es) | Moduladores de nlrp3 | |
CO2019013317A2 (es) | Oligonucleótidos antisentido para la modulación de la expresión de htra1 | |
CL2020000085A1 (es) | Moduladores de nlrp3. | |
CO2017005588A2 (es) | 2-amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
CO2021014008A2 (es) | Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento | |
BR112017007014A2 (pt) | derivados de benzotiofenila substituídos como agonistas do gpr40 para o tratamento de diabetes tipo ii | |
ECSP16074207A (es) | Pirazinas moduladoras de gpr6 | |
UY36081A (es) | Compuestos inhibidores de metaloenzima como fungicidas. | |
AR112908A1 (es) | Oligonucleótidos antisentido para modular la expresión de htra1 | |
CR20170354A (es) | Derivados de tetrahidropiranil benzamida | |
NI201400145A (es) | Compuestos y composiciones que modulan la actividad del receptor del factor de crecimiento epidérmico |